沃华医药(002107) - 2024 Q2 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is estimated to be 8.90 million yuan, a decrease of 76.08% to 64.52% compared to the same period last year, which was 37.20 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be 8.20 million yuan, down by 77.02% to 66.38% from 35.69 million yuan in the previous year [2]. - The basic earnings per share is expected to be 0.0154 yuan, a decline from 0.0645 yuan per share in the same period last year [2]. Product Performance - The core product, WoHua XinKeShu Pian, experienced a price reduction of approximately 39% due to winning a centralized procurement bid, leading to a decrease in sales revenue [4]. - The reduction in gross profit contribution has resulted in a decline in operating profit [5]. Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [6]. - The above forecast data is preliminary and the specific financial data will be disclosed in the company's 2024 semi-annual report [7].